Day One Biopharmaceuticals Company Profile

Background

Founded in 2018, Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with life-threatening diseases. The company's mission is to address the lack of new therapies resulting from the traditional drug development model, which has left children with cancer and their families waiting too long for new treatments. Day One aims to accelerate better, targeted treatments so patients of any age can look forward from 'day one' to the future they've envisioned.

Key Strategic Focus

Day One's strategic focus centers on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. The company employs a "search & development" strategy to identify, acquire, and develop potential best- or first-in-class programs, aiming to introduce new medicines that will make a real difference in the treatment of children and adults.

Financials and Funding

As of April 2025, Day One Biopharmaceuticals reported annual revenue of approximately $15 million. The company has raised a total of $175 million in funding over five rounds, with the latest funding round occurring on July 30, 2024, amounting to $175 million.

Stock market information for Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc is a equity in the USA market.

The price is 6.62 USD currently with a change of 0.04 USD (0.01%) from the previous close.

The latest open price was 6.63 USD and the intraday volume is 1549641.

The intraday high is 6.73 USD and the intraday low is 6.515 USD.

The latest trade time is Thursday, July 17, 00:15:00 UTC.

Pipeline Development

Day One's lead product candidate is tovorafenib, an oral, brain-penetrant type II pan-rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. Tovorafenib is in a Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma and in a Phase III clinical trial for frontline RAF-altered pediatric low-grade glioma (pLGG). Additionally, the company is developing DAY301, which is in a Phase I clinical trial for adult and pediatric cancers, and a VRK1 inhibitor in the pre-clinical stage for adult and pediatric cancers.

Technological Platform and Innovation

Day One Biopharmaceuticals leverages a "search & development" strategy to identify and develop breakthrough medicines aimed at improving outcomes for patients of all ages facing serious diseases. This approach enables the company to find, acquire, and develop potential best- or first-in-class programs, with the goal of introducing new medicines that will make a real difference in the treatment of children and adults.

Leadership Team

Day One's leadership team comprises seasoned professionals with extensive experience in the biopharmaceutical industry:

Jeremy Bender, PhD, MBA: Chief Executive Officer

Elly Barry, MD: Chief Medical Officer

Davy Chiodin, PharmD: Chief Development Officer

Adam Dubow: General Counsel

Lauren Merendino, MBA: Chief Commercial Officer

Jaa Roberson: Chief People Officer

John Stubenrauch: Chief Technology Officer

Michael Vasconcelles, MD: Head of Research and Development

Charles N. York II, MBA: Chief Operating and Financial Officer

Leadership Changes

In June 2025, Day One appointed Dr. Michael Vasconcelles as Head of Research and Development. Dr. Vasconcelles brings over 25 years of extensive oncology research, development, and health technology expertise to the company.

Competitor Profile

Market Insights and Dynamics

The global oncology market was valued at $286.05 billion in 2022, with projected growth to $522.21 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 7.4%, indicating a highly competitive and rapidly evolving landscape.

Competitor Analysis

Day One Biopharmaceuticals faces competition from several established and emerging companies:

Kite Pharma: A subsidiary of Gilead Sciences, Kite Pharma specializes in cancer immunotherapy products, including chimeric antigen receptor (CAR) T-cell therapies.

CytomX Therapeutics: Focuses on developing conditionally activated antibody therapeutics for the treatment of cancer.

bluebird bio: Develops gene therapies for severe genetic diseases and cancer.

Bexion Pharmaceuticals: Committed to the discovery, clinical development, and acquisition of oncology treatments.

CARsgen Therapeutics: A clinical-stage immuno-oncology company developing chimeric T-cell antigen receptor therapies for various cancers.

OncoTherapy Science: Engaged in research and development of cancer therapeutics.

Calidi Biotherapeutics: Specializes in oncolytic virus-based immunotherapies for cancer.

Strategic Collaborations and Partnerships

Day One Biopharmaceuticals has formed strategic partnerships to enhance its research and development capabilities:

Children's Brain Tumor Network: A collaboration aimed at advancing research in pediatric brain tumors.

Sprint Bioscience AB: A partnership focused on developing new cancer treatments.

Operational Insights

Day One's focus on pediatric oncology positions it uniquely in a market with significant unmet needs. The company's emphasis on targeted therapies offers a competitive edge by providing effective treatments with fewer side effects. However, as a relatively young company, Day One has a limited number of products on the market, which could restrict revenue generation in the short term. The company's future growth is heavily reliant on the successful development and approval of its drug candidates, which carries inherent risks.

Strategic Opportunities and Future Directions

Opportunities for growth lie in the increasing demand for pediatric cancer treatments and advancements in biotechnology that can enhance Day One’s research and development capabilities. The company has the potential to expand its offerings beyond pediatric oncology, exploring treatments for adult cancers or other therapeutic areas. However, Day One must navigate challenges such as intense competition, regulatory hurdles, and economic factors that could impact its ability to raise capital and invest in research and development.